Rosacea is a rash involving the central face that most often starts between the age of 30 and 60 years. It is common in those with fair skin, blue eyes and Celtic origins. It may be transient, recurrent or persistent and is characterized by its color, red. The disorder is more frequently diagnosed in women, but tends to be more severe in men. There is also evidence that rosacea may tend to run in families, and may be especially prevalent in people of northern or eastern European descent.
Some of the key facts of Rosacea market report
1. The total prevalent population of Rosacea in the 7MM was 47,634,256 in 2017.2. The prevalence of Rosacea was found in the United States with 16,652,170 cases in 2017.3. Germany had a prevalent population of Rosacea with 8,383,943 cases in 2017.4. France had Rosacea prevalent population of 6,082,002 cases in 2017.5. Italy had a prevalent population of Rosacea with 3,217,083 cases in 2017.
Request for sample pages
Key benefits of the report
1. Rosacea market report covers a descriptive overview and comprehensive insight of the Rosacea epidemiology and Rosacea market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)2. Rosacea market report provides insights into the current and emerging therapies.3. Rosacea market report provides a global historical and forecasted market covering drug outreach in 7 MM.4. Rosacea market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Rosacea market.
The current Rosacea therapeutic landscape can be divided into four major categories based on the route of administration and the approved usage for the condition. These are topical retinoids, topical antibiotics, oral tetracycline-class antibiotics (TCAs), and oral retinoids.
Among Topical therapies, topical retinoids mainly include Tretinoin, Tazarotene, Adapalene, and Clindamycin/tretinoin, and several others are used to reduce erythema, papules and pustules, and telangiectasias. Among these, Tretinoin has the lowest cost and most commonly prescribed topical retinoid, accounting for the majority of the population.
Topical antibiotics, such as metronidazole (e.g. Metrolotion), clindamycin, erythromycin, azelaic acid (e.g. Fincea), benzoyl peroxide, benzoyl peroxide/clindamycin, benzoyl peroxide/erythromycin, sulfacetamide, and sulfacetamide/sulfur, are applied directly to the skin to kill bacteria on the surface of the skin.
Topical antibiotics are the most commonly prescribed class of drug for all sexes and age groups. The most common topical antibiotics prescribed are metronidazole (for an estimated half of the population of topical antibiotics) followed by clindamycin, erythromycin, and azelaic acid.
Table of contents
1. Key Insights2 Executive Summary of Rosacea3. Rosacea Market Overview at a Glance4. Rosacea Disease Background and Overview: Rosacea5. Rosacea Epidemiology and Patient Population6. Country Wise-Epidemiology of Rosacea Disease6.1. United States6.2. EU5 Countries6.2.1. Germany6.2.2. France6.2.3. Italy6.2.4. Spain6.2.5. United Kingdom6.3. Japan7. Rosacea Treatment Algorithm, Current Treatment, and Medical Practices8. Unmet Needs9. Rosacea Marketed Drugs9.1. Rhofade: Allergan9.2. Oracea: Galderma Laboratories (Nestle Skin Health)9.3. Mirvaso: Galderma Laboratories (Nestle Skin Health)9.4. Finacea: Bayer9.5. Soolantra: Galderma Laboratories, Inc. (Nestle Skin Health)9.6. Metrogel: Galderma Laboratories (Nestle Skin Health)10. Key Cross Competition11. Rosacea Emerging Drugs11.1. FMX103: Foamix Pharmaceuticals11.2. Epsolay: Sol-Gel11.3. ACU-D1: Accuitis11.4. HY01: Hovione Scientia Limited11.5. AFX-4031: Afecta Pharmaceuticals11.6. AOB103: AOBiome12. Rosacea 7 Major Market Analysis13. The United States Market Outlook14. EU-5 Countries: Market Outlook14.1. Germany14.2. France14.3. Italy14.4. Spain14.5. United Kingdom15. Japan: Market Outlook16. Access and Reimbursement Overview of Rosacea17. Rosacea Market Drivers18. Rosacea Market Barriers19. SWOT Analysis20. Appendix21. DelveInsight Capabilities22. Disclaimer23. About DelveInsight
Media ContactCompany Name: DelveInsightContact Person: Priya MauryaEmail: Send EmailPhone: +919650213330City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/